Relevance of KRAS status in relation to clinical outcome of anti-VEGF-based therapy of metastatic disease in patients with right-sided primary colorectal cancer
| Autor: | Beatric Benscikova, Lenka Ostrizkova, Karel Hejduk, Lubos Petruzelka, Michal Vocka, Radka Obermannova, Lenka Zdrazilova-Dubska, Igor Kiss, Renata Chloupková |
|---|---|
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 36:785-785 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.4_suppl.785 |
| Popis: | 785 Background: Right-sided location of primary colorectal carcinoma is associated with worse prognosis and predicts worse outcome of treatment of metastatic disease. Prognostic role of KRAS status in 1st-line treatment with anti-VEGF of mCRC remains controversial. We aim to study prognostic role of KRAS in the context of primary tumor location for anti-VEGF-based therapy of mCRC. Methods: Data from 3 national comprehensive cancer centers in the Czech Republic were collected prospectively from 01/2009 - 09/2015. A retrospective analysis of outcomes of 1059 pts with mCRC with known KRAS status was performed. Patients were treated with 1st-line bevacizumab (bev) plus FOLFOX or CapOx, irrespective of the KRAS status (all-RAS since 2015). The primary objective of our retrospective analysis was assessment of OS and PFS in right-sided primary tumors in connection with KRAS status. OS and PFS were calculated using the Kaplan-Meier method. Results: KRAS mutation was significantly more common in right- vs left-sided mCRC. Unlike in left-sided subgroup, both PFS and OS was poor in right-sided subgroup irrespective of KRAS status. Targeted therapy in subsequent lines of treatment was evenly spread among primary location subgroups. 769 (71.4%) patients were treated by CTx alone. Conclusions: Known KRAS status (Table) is not relevant for the treatment with 1st-line anti-VEGF plus CTx in righ-sided primary tumors. [Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|